296 related articles for article (PubMed ID: 33677256)
1. (-)-Epigallocatechin-3-gallate inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing NF-κB and MAPK signaling pathways.
Xu H; Liu T; Jia Y; Li J; Jiang L; Hu C; Wang X; Sheng J
Int Immunopharmacol; 2021 Jun; 95():107464. PubMed ID: 33677256
[TBL] [Abstract][Full Text] [Related]
2. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
[TBL] [Abstract][Full Text] [Related]
3. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
[TBL] [Abstract][Full Text] [Related]
4. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways.
Xu H; Chen F; Liu T; Xu J; Li J; Jiang L; Wang X; Sheng J
Chem Biol Interact; 2020 Nov; 331():109235. PubMed ID: 32971123
[TBL] [Abstract][Full Text] [Related]
5. Niloticin inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways.
Xu H; Jia Y; Li J; Huang X; Jiang L; Xiang T; Xie Y; Yang X; Liu T; Xiang Z; Sheng J
Biomed Pharmacother; 2022 May; 149():112902. PubMed ID: 35364377
[TBL] [Abstract][Full Text] [Related]
6. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
7. Guaiacol suppresses osteoclastogenesis by blocking interactions of RANK with TRAF6 and C-Src and inhibiting NF-κB, MAPK and AKT pathways.
Zhi X; Fang C; Gu Y; Chen H; Chen X; Cui J; Hu Y; Weng W; Zhou Q; Wang Y; Wang Y; Jiang H; Li X; Cao L; Chen X; Su J
J Cell Mol Med; 2020 May; 24(9):5122-5134. PubMed ID: 32185887
[TBL] [Abstract][Full Text] [Related]
8. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
9. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
[TBL] [Abstract][Full Text] [Related]
10. (-)-Epigallocatechin-3-Gallate Decreases Osteoclastogenesis via Modulation of RANKL and Osteoprotegrin.
Chen ST; Kang L; Wang CZ; Huang PJ; Huang HT; Lin SY; Chou SH; Lu CC; Shen PC; Lin YS; Chen CH
Molecules; 2019 Jan; 24(1):. PubMed ID: 30609798
[TBL] [Abstract][Full Text] [Related]
11. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
12. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells.
Nikhil K; Sharan S; Roy P
Pharmacol Rep; 2015 Dec; 67(6):1264-72. PubMed ID: 26481551
[TBL] [Abstract][Full Text] [Related]
13. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
[TBL] [Abstract][Full Text] [Related]
14. Carnosic acid attenuates RANKL-induced oxidative stress and osteoclastogenesis via induction of Nrf2 and suppression of NF-κB and MAPK signalling.
Thummuri D; Naidu VGM; Chaudhari P
J Mol Med (Berl); 2017 Oct; 95(10):1065-1076. PubMed ID: 28674855
[TBL] [Abstract][Full Text] [Related]
15. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
16. Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways.
Zhou C; Liu W; He W; Wang H; Chen Q; Song H
Int Immunopharmacol; 2015 Mar; 25(1):49-54. PubMed ID: 25617149
[TBL] [Abstract][Full Text] [Related]
17. Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-κB and MAPK signaling pathway.
Zhao S; Sun Y; Li X; Wang J; Yan L; Zhang Z; Wang D; Dai J; He J; Wang S
Int Immunopharmacol; 2016 Nov; 40():458-465. PubMed ID: 27728897
[TBL] [Abstract][Full Text] [Related]
18. (-)-Epigallocatechin-3-gallate inhibits RANKL-induced osteoclastogenesis via downregulation of NFATc1 and suppression of HO-1-HMGB1-RAGE pathway.
Nishioku T; Kubo T; Kamada T; Okamoto K; Tsukuba T; Uto T; Shoyama Y
Biomed Res; 2020; 41(6):269-277. PubMed ID: 33268671
[TBL] [Abstract][Full Text] [Related]
19. Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-κB and MAPK signaling pathways.
Xu Q; Chen G; Liu X; Dai M; Zhang B
Biochem Biophys Res Commun; 2019 Jan; 508(3):902-906. PubMed ID: 30538045
[TBL] [Abstract][Full Text] [Related]
20. Dencichine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis by inhibiting RANKL-associated NF-κB and MAPK signaling pathways.
Cang D; Zou G; Yang C; Shen X; Li F; Wu Y; Ji B
J Pharmacol Sci; 2021 Aug; 146(4):206-215. PubMed ID: 34116734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
